Skip to main content

Table 3 Distribution of clinicopathological parameters: CA IX positive versus CA IX negative high-risk breast cancer patients

From: Carbonic anhydrase IX and response to postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of the DBCG82 b and c trials

  

CA IX positive

CA IX negative

χ2/P value

All

 

151 (16%)

794 (84%)

 

Protocol

Pre (DBCG82b)

89 (59%)

447 (56%)

0.5

 

Post (DBCG82c)

62 (41%)

347 (44%)

 

Tumour size (mm)

<21

48 (32%)

289 (36%)

0.5

 

21 to 50

81 (54%)

393 (49%)

 
 

>50

22 (15%)

112 (14%)

 

Positive nodes

None

6 (3%)

50 (6%)

0.5

 

1 to 3

70 (46%)

346 (44%)

 
 

>3

75 (50%)

398 (50%)

 

Histopathology

Ductal

133 (88%)

680 (86%)

0.4

 

Nonductal

18 (12%)

114 (14%)

 

Malignancy grade

Grade 1

18 (12%)

166 (21%)

P < 0.0001

 

Grade 2

56 (37%)

357 (45%)

 
 

Grade 3

59 (39%)

157 (20%)

 
 

Nonductal

18 (12%)

114 (14%)

 

ER

Positive

50 (33%)

581 (73%)

P < 0.0001

 

Negative

101 (67%)

213 (27%)

 

PgR

Positive

47 (31%)

506 (64%)

P < 0.0001

 

Negative

104 (69%)

288 (36%)

 

HER2

Negative

101 (33%)

636 (80%)

P < 0.0001

 

Positive

50 (67%)

636 (80%)

 
  1. Shown is the distribution of various clinicopathological parameters among carbonic anhydrase (CA) IX positive and CA IX negative high-risk breast cancer patients randomized to receive or not receive postmastectomy radiotherapy. ER, oestrogen receptor; HER, human epidermal growth factor; PgR, progesterone receptor.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us